NCT05968703 · RECRUITING

Combined STN and NBM Deep Brain Stimulation for Mild Cognitive Impairment in Parkinson's Disease

This trial is testing whether adding a second set of brain stimulation electrodes, targeting a memory-related brain region called the Nucleus Basalis of Meynert, is safe and tolerable alongside the standard deep brain stimulation surgery already used for Parkinson's motor symptoms. It is a Phase NA, meaning it is an early feasibility study focused on safety, not yet testing whether it works. Only ten participants are planned.

You may qualify if

  • Diagnosis of Parkinson's disease (PD)
  • Approved (or planning on) for subthalamic nucleus (STN) deep brain stimulation (DBS)
  • Willingness to withdraw from clinical medication regimen when necessary for research visits
  • Ability to provide informed consent

You're excluded if

  • Dementia
  • Unstable medical, psychiatric conditions including significant untreated depression, history of suicidal attempt, or current suicide ideation
  • History of seizures
  • Pregnant
  • Requires MRI
  • Unable to walk 100 feet without an assistive device

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2025-05-30

View full record on ClinicalTrials.gov

All APOE4 clinical trials